The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 18, Issue 1, 2012, Pages 112-119

  Wang, Lijian ^a   Trebicka, Estela ^a   Fu, Ying ^a   Ellenbogen, Shiri ^a   Hong, Charles C ^b   Babitt, Jodie L ^a   Lin, Herbert Y ^a   Cherayil, Bobby J ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

bone morphogenetic protein; hepcidin; inflammation; iron

Indexed keywords

AGENTS USED IN INFLAMMATORY BOWEL DISEASE; BONE MORPHOGENETIC PROTEIN 6; HEPCIDIN; INTERLEUKIN 6; IRON; LDN 193189; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; IRON BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEIN 6; COLITIS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; IRON; MALE; MICE; MICE, INBRED C57BL; PYRAZOLES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 83555172379     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21675     Document Type: Article

References (41)

1. Stein J, Hartmann F, Dignass AU,. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010; 7: 599-610.
2. Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of mammalian iron metabolism. Cell. 2010; 142: 24-38.
3. Ganz T, Nemeth E,. Iron sequestration and anemia of inflammation. Semin Hematol. 2009; 46: 387-393.
4. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306: 2090-2093. (Pubitemid 40007660)
5. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 13: 399-408. (Pubitemid 26256612)
6. Schmidt PJ, Toran PT, Giannetti AM, et al. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab. 2008; 7: 205-214. (Pubitemid 351285524)
7. Gao J, Chen J, Kramer M, et al. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab. 2009; 9: 217-227.
8. Pietrangelo A,. Hereditary hemochromatosis: pathogenesis, diagnosis and treatment. Gastroenterology. 2010; 139: 393-408.
9. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006; 38: 531-539.
10. Babitt JL, Huang FW, Xia Y, et al. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007; 117: 1933-1939. (Pubitemid 47036327)
11. Corradini E, Garuti C, Montosi G, et al. Bone morphogenetic protein signaling is impaired in an HFE knock-out mouse model of hemochromatosis. Gastroenterology. 2009; 137: 1489-1497.
12. Ryan JD, Ryan E, Fabre A, et al. Defective bone morphogenetic protein signaling underlies hepcidin deficiency in HFE hereditary hemochromatosis. Hepatology. 2010; 52: 1266-1273.
13. Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009; 41: 482-487.
14. Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009; 41: 478-481.
15. Corradini E, Schmidt PJ, Meynard D, et al. BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knock-out mice. Gastroenterology. 2010; 139: 1721-1729.
16. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113: 1271-1276. (Pubitemid 39069926)
17. Lee P, Peng H, Gelbart T, et al. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A. 2005; 102: 1906-1910. (Pubitemid 40261985)
18. Wrighting DM, Andrews NC,. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006; 108: 3204-3209.
19. Zhou XY, Tomatsu S, Fleming RE, et al. HFE gene knock-out produces a mouse model of hereditary hemochromatosis. Proc Natl Acad Sci U S A. 1998; 95: 2492-2497. (Pubitemid 28145969)
20. Wang L, Johnson EE, Shi HN, et al. Attenuated inflammatory responses in hemachromatosis reveal a role for iron in the regulation of macrophage cytokine translation. J Immunol. 2008; 181: 2723-2731.
21. Wang L, Harrington L, Trebicka E, et al. Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis. J Clin Invest. 2009; 119: 3322-3328.
22. Cherayil BJ,. Cross-talk between iron homeostasis and intestinal inflammation. Gut Microbes. 2010; 1: 65-69.
23. Ostanin DV, Bao J, Koboziev I, et al. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009; 296: G135-G146.
24. Yu PB, Hong CC, Sachidanandan C, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008; 4: 33-41. (Pubitemid 350273653)
25. Kautz L, Meynard D, Monnier A, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of BMP6, Smad7, Id1 and Atoh8 in the mouse liver. Blood. 2008; 112: 1503-1509.
26. Khader SA, Pearl JE, Sakamoto K, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol. 2005; 175: 788-795. (Pubitemid 41094960)
27. Li Q, Cherayil BJ,. Role of Toll-like receptor 4 in macrophage activation and tolerance during Salmonella enterica serovar Typhimurium infection. Infect Immun. 2003; 71: 4873-4882. (Pubitemid 37070728)
28. Miyazono K, Kamiya Y, Morikawa M,. Bone morphogenetic protein receptors and signal transduction. J Biochem. 2010; 147: 35-51.
29. Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006; 12: 1101-1106. (Pubitemid 44847466)
30. Arnold J, Sangwaiya A, Bhatkal B, et al. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homeostasis. Eur J Gastroenterol Hepatol. 2009; 21: 335-339.
31. Hapfelmeier S, Hardt WD,. A mouse model for S. typhimurium-induced enterocolitis. Trends Microbiol. 2005; 13: 497-503. (Pubitemid 41317528)
32. Berg DJ, Zhang J, Weinstock JV, et al. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology. 2002; 123: 1527-1542. (Pubitemid 35231653)
33. Hale LP, Gottfried MR, Swidsinski A,. Piroxicam treatment of IL-10-deficient mice enhances colonic epithelial apoptosis and mucosal exposure to intestinal bacteria. Inflamm Bowel Dis. 2005; 11: 1060-1069. (Pubitemid 41682562)
34. De Domenico I, Zhang TY, Koening CL, et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest. 2010; 120: 2395-2405.
35. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2005; 2: 399-409.
36. Verga Falzacappa MV, Casanovas G, Hentze MW, et al. A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J Mol Med. 2008; 86: 531-540.
37. Oldenburg B, van Berge Henegouwen GP, Rennick D, et al. Iron supplementation affects the production of pro-inflammatory cytokines in IL-10-deficient mice. Eur J Clin Invest. 2000; 30: 505-510. (Pubitemid 30330464)
38. Carrier J, Aghdassi E, Cullen J, et al. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr. 2002; 132: 3146-3150.
39. Erichsen K, Hausken T, Ulvik RJ, et al. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn's disease. Scand J Gastroenterol. 2003; 38: 543-548. (Pubitemid 36609862)
40. Uritski R, Barshack I, Bilkis I, et al. Dietary iron affects inflammatory status in a rat model of colitis. J Nutr. 2004; 134: 2251-2255. (Pubitemid 39201593)
41. Seril DN, Liao J, West AB, et al. High-iron diet: foe or feat in ulcerative colitis and ulcerative colitis-associated carcinogenesis. J Clin Gastroenterol. 2006; 40: 391-397. (Pubitemid 44318157)